FDA accelerated approval vs full approval: what the words mean

This is not clinical evidence and not medical advice. It does not replace your care team. Discuss anything here with your clinician before you act on it. An approval headline lands in your feed. Or someone on your team mentions that a drug was approved. On its drug review page, FDA describes the step this way: a developer with evidence that a drug is safe and effective for its intended use can file an application to market it, and the FDA review team examines all the submitted data and decides whether to approve. A New Drug Application, FDA says, is meant to demonstrate safety and effectiveness for the intended use in the population studied. So the decision is about the drug for that use and that population, not about any one reader. FDA says the resulting labeling describes the basis for approval and how best to use the drug. Pathway names like accelerated approval or fast track describe how FDA regulates drugs in general, not how a drug will work for you. Consider asking your care team who was studied, and whether that group looks like you.

NCI's dictionary calls accelerated approval an official process that lets FDA approve a new drug before it has gone through all of the required levels of testing in humans. It is used only for drugs that treat serious or life-threatening diseases where other treatments may not be available or may no longer be effective, NCI says. FDA's program page adds the mechanism: earlier approval for drugs that treat serious conditions and fill an unmet medical need, based on a surrogate endpoint, which can considerably shorten the time before approval. A 2012 law also lets the decision rest on an intermediate clinical endpoint, which FDA describes as a measure of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug. FDA's December 2024 guidance page calls accelerated approval one of its expedited programs for serious or life-threatening conditions.

FDA describes a surrogate endpoint as a marker, such as a laboratory measurement, radiographic image or physical sign, that is thought to predict clinical benefit but is not itself a measure of clinical benefit. NCI names a shrinking tumor and lower biomarker levels as surrogate examples, used instead of stronger indicators like longer survival or better quality of life because they can be measured sooner. FDA's own example is approval based on tumor shrinkage, which it calls reasonably likely to predict a real clinical benefit and which can come far sooner than learning whether patients lived longer. The company still has to run studies to confirm that shrinkage actually predicts that patients live longer. NCI cautions that surrogate endpoints are not always true indicators of how well a treatment works. For how a study's main outcome works, see our answers page "How to read a study abstract before you trust the headline". The difference here is that an accelerated approval can rest on a stand-in measure, so I would want the endpoint named up front. Which endpoint the approval used is a fair thing to ask your team.

"Full approval" is how people often say it. FDA's own term on the pages I read is "traditional approval," and its program page says FDA grants traditional approval if the confirmatory trial shows the drug actually provides clinical benefit. FDA says it can take many years to learn whether a drug changes how a patient survives, feels or functions, which is what FDA calls clinical benefit. So under accelerated approval, drug companies are still required to run studies that confirm the anticipated benefit. FDA decides whether to accept a proposed surrogate or intermediate endpoint based on the scientific support for it, and the studies showing an effect on that endpoint must be adequate and well controlled. Where the confirmatory studies verify clinical benefit, FDA's patient page says it will generally terminate the requirement. Whether the confirmatory study is underway, and what it measures, is worth asking about.

FDA's patient page says approval may be withdrawn, or the labeled indication changed, if trials fail to verify clinical benefit or do not show enough benefit to justify the drug's risks. Its example is a significantly smaller size or duration of benefit than was expected from the effect on the surrogate. The program page says FDA has regulatory procedures in place that could lead to removing the drug from the market. Separately, FDA's December 2024 guidance covers the procedures for expedited withdrawal and the changes Congress made through the Consolidated Appropriations Act, 2023. None of those pages is a forecast for any one drug or person. Consider asking your care team what the plan would be if confirmatory results came out differently.

Priority review is about the review clock. FDA's Priority Review page says the designation means FDA's goal is to act on an application within 6 months, compared with 10 months under standard review. FDA says the designation directs overall attention and resources to applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of treating, diagnosing or preventing serious conditions. The wording is "if approved": it describes what FDA looks for in an application, not a finding that the drug is better. The page also says it does not affect the length of the clinical trial period. On the bar for approval, FDA's wording is direct: a Priority designation does not alter the scientific or medical standard for approval or the quality of evidence necessary. A headline that says priority review is telling you about the clock. What it means for the evidence behind this particular drug is a question for your care team.

FDA's overview page names four approaches: priority review, breakthrough therapy, accelerated approval and fast track. It says that because each implies speed, there can be confusion about what each one means. Fast track, per FDA, is designed to facilitate development and expedite review of drugs for serious conditions that fill an unmet medical need, and the drug company has to request it. Features include more frequent meetings with FDA and rolling review, where completed sections of an application can be submitted as they are ready. Breakthrough therapy designation, also requested by the company, is for serious conditions where preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint. It is eligible for all fast track features plus intensive guidance on an efficient development program. FDA states that priority designation doesn't change the standard for approval on the Priority Review page. I haven't seen that said on the other pages, so I won't claim it for them.

If a label or announcement says accelerated approval, that is worth noticing. FDA's description of the drug review step says labeling accurately and objectively describes the basis for approval and how best to use the drug. That page is general and isn't about accelerated approvals, and nothing I read says what any one label contains. FDA's Accelerated Approval Program page has a Cancer Accelerated Approvals section that lists Ongoing, Verified Clinical Benefit, Withdrawn and Other. FDA's Accelerated Approvals page hosts reports on approvals based on a surrogate endpoint, updated quarterly in January, April, July and October. Consider asking: Was this approval based on a surrogate or intermediate endpoint, or on a measured clinical benefit? Is a confirmatory study underway, and what is it measuring? What population does the approval cover?

If I were bringing an approval announcement to a visit, I would write the endpoint's name at the top of the page. Consider asking: What was the approval based on? Is it accelerated approval, and if so, what has to be confirmed? Who was in the studies, and how do I compare? What would change the plan if the confirmatory results came out differently? If the announcement quotes a percent reduction in risk, see our blog piece "Absolute risk vs relative risk in cancer headlines". For what the trial phases mean, see "What changes from Phase 1 to Phase 3". This page is not a clinical review of any drug, and nothing here says which option is right for you.